CytoDyn (CYDY) awards 3.25M stock options to Chief Legal Officer

Rhea-AI Filing Summary

CytoDyn Inc. reported that Chief Legal Officer Tyler Blok received a grant of non-qualified stock options as part of his fiscal 2026 compensation. The award covers 3,249,794 options to buy common stock at an exercise price of $0.28 per share, expiring in 2036.

The grant was approved by the Compensation Committee on March 20, 2026 under CytoDyn’s 2012 Equity Incentive Plan. 812,448 underlying shares will vest on March 20, 2027, with the remaining options vesting in roughly equal monthly installments from April 2027 through March 2030, subject to continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Blok Tyler

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified stock option (right to buy)	3,249,794	$0.00	--

Holdings After Transaction: Non-qualified stock option (right to buy) — 3,249,794 shares (Direct)

Footnotes (1)

1. This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan"). 812,448 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blok Tyler

(Last) (First) (Middle)

1111 MAIN STREET, SUITE 660

(Street)

VANCOUVER WASHINGTON 98660

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytoDyn Inc. [ CYDY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified stock option (right to buy)	$0.28	03/20/2026		A		3,249,794(1)		(2)	03/20/2036	Common Stock	3,249,794	$0	3,249,794	D

Explanation of Responses:

1. This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").

2. 812,448 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.

	/s/ Tyler Blok	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CytoDyn (CYDY) disclose for Tyler Blok?

CytoDyn disclosed that Chief Legal Officer Tyler Blok received a large non-qualified stock option grant. The award represents part of his fiscal 2026 compensation and gives him the right to purchase CytoDyn common shares at a fixed exercise price if vesting conditions are met.

How many stock options did CytoDyn (CYDY) grant to its Chief Legal Officer?

CytoDyn granted Tyler Blok 3,249,794 non-qualified stock options. Each option relates to one share of common stock, creating a substantial potential equity position if fully vested and exercised in the future under the company’s 2012 Equity Incentive Plan.

What is the exercise price and term of Tyler Blok’s CytoDyn (CYDY) options?

The options granted to Tyler Blok have an exercise price of $0.28 per share. They are scheduled to expire in 2036, providing a long exercise window if vesting and continued service requirements under CytoDyn’s 2012 Equity Incentive Plan are satisfied.

How do the CytoDyn (CYDY) options granted to Tyler Blok vest over time?

Of the 3,249,794 options, 812,448 underlying shares will vest on March 20, 2027. The remaining balance vests in approximately equal monthly installments from April 2027 through March 2030, conditioned on Mr. Blok’s continuous service to the company.

Under which plan were CytoDyn (CYDY) stock options granted to the Chief Legal Officer?

The option grant to Chief Legal Officer Tyler Blok was made under CytoDyn’s 2012 Equity Incentive Plan, as amended. This plan reserves shares specifically for issuance to employees, directors, and certain outside consultants as part of long-term equity-based compensation programs.

Was the CytoDyn (CYDY) stock option grant to Tyler Blok a routine compensation award?

Yes. The company states the grant represents the annual award for fiscal 2026, consistent with past practice. It was approved by the Compensation Committee and structured under the existing 2012 Equity Incentive Plan used for recurring employee and director equity compensation.